Literature DB >> 31190177

PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.

Amir Iravani1,2, Guy-Anne Turgeon3, Tim Akhurst4, Jason W Callahan4, Mathias Bressel5, Sarah J Everitt6,7,8, Shankar Siva6,3, Michael S Hofman4, Rodney J Hicks4,6, David L Ball6,3, Michael P Mac Manus6,3.   

Abstract

PURPOSE: Inflammatory FDG uptake in the lung (PET-pneumonitis) following curative-intent radiotherapy (RT)/chemo-RT (CRT) in non-small cell lung cancer (NSCLC) can pose a challenge in FDG-PET/CT response assessment. The aim of this study is to describe different patterns of PET-pneumonitis to guide the interpretation of FDG-PET/CT and investigate its association with tumor response and overall survival (OS).
METHODS: Retrospective analysis was performed on 87 NSCLC patients in three prospective trials who were treated with radical RT (n = 7) or CRT (n = 80), with baseline and post-treatment FDG-PET/CT. Visual criteria were performed for post-treatment FDG-PET/CT response assessment. The grading of PET-pneumonitis was based on relative lung uptake intensity compared to organs of reference and classified as per Deauville score from grade 1-5. Distribution patterns of PET-pneumonitis were defined as follows: A) patchy/sub-pleural; B) diffuse (involving more than a segment); and C) peripheral (diffusely surrounding a photopenic region).
RESULTS: Follow-up FDG-PET/CT scans were performed approximately 3 months (median, 89 days; interquartile range, 79-93) after RT. Overall, PET-pneumonitis was present in 62/87 (71%) of patients, with Deauville 2 or 3 in 12/62 (19%) and 4 or 5 in 50/62 (81%) of patients. The frequency of patterns A, B and C of PET-pneumonitis was 19/62 (31%), 20/62 (32%) and 23/62 (37%), respectively. No association was found between grade or pattern of PET-pneumonitis and overall response at follow-up PET/CT (p = 0.27 and p = 0.56, respectively). There was also no significant association between PET-pneumonitis and OS (hazard ratio [HR], 1.3; 95% confidence interval [CI], 0.6-2.5; p = 0.45). Early FDG-PET/CT response assessment, however, was prognostic for OS (HR, 1.7; 95% CI, 1.2-2.2; p < 0.001).
CONCLUSION: PET-pneumonitis is common in early post-CRT/RT, but pattern recognition may assist in response assessment by FDG-PET/CT. While FDG-PET/CT is a powerful tool for response assessment and prognostication, PET-pneumonitis does not appear to confound early response assessment or to independently predict OS.

Entities:  

Keywords:  FDG-PET/CT; Non-small cell lung cancer (NSCLC); PET response assessment; PET-pneumonitis; Radiation pneumonitis

Mesh:

Substances:

Year:  2019        PMID: 31190177     DOI: 10.1007/s00259-019-04388-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  5 in total

1.  Predictive Value of 18F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.

Authors:  Jang Yoo; Jaeho Lee; Miju Cheon; Sang-Keun Woo; Myung-Ju Ahn; Hong Ryull Pyo; Yong Soo Choi; Joung Ho Han; Joon Young Choi
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

Review 2.  Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine.

Authors:  Haoyue Guo; Kandi Xu; Guangxin Duan; Ling Wen; Yayi He
Journal:  Ann Nucl Med       Date:  2021-11-02       Impact factor: 2.668

Review 3.  Thoracic positron emission tomography: 18F-fluorodeoxyglucose and beyond.

Authors:  Timothy J Jaykel; Michael S Clark; Daniel A Adamo; Brain T Welch; Scott M Thompson; Jason R Young; Eric C Ehman
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

Review 4.  Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Authors:  Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-13       Impact factor: 10.057

Review 5.  The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments.

Authors:  V Mohan; N M Bruin; J B van de Kamer; J-J Sonke; Wouter V Vogel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-09       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.